CSL Limited Annual Report 2022/23 56 9 Social The influenza virus can change significantly each year, making it critical for CSL Seqirus to assess seasonal vaccine effectiveness through real world evidence (RWE), year after year. As a company on the front line of influenza prevention, CSL Seqirus is committed to using RWE to continually evaluate the clinical benefit and cost effectiveness of our innovative seasonal influenza vaccines compared to more traditional options. RWE can be a valuable tool in helping health agencies make decisions about which influenza vaccines to recommend for certain populations, providing access for the most vulnerable groups through government-funded immunisation programs. In October 2022, CSL Seqirus undertook a modelling study using RWE to understand the impact of co-circulation of influenza and COVID-19 on healthcare resources in the winter months in the UK. The study, now published, is helping governments understand the pressures their healthcare systems will be placed under and the broader value of robust immunisation program as we learn to adjust to this new reality. In March 2023, CSL Seqirus partnered with a member of the European Parliament to produce a multistakeholder symposium at the European Parliament entitled ‘Better Decision-Making for Better Outcomes: Harnessing the Power of RWE’ at which a European Union-wide call to action for more systematic use of RWE by policy makers, regulators and payers was launched. The role of real-world evidence in driving vaccine value and access The CSL Vifor Patient Academy offers employees the unique opportunity to learn directly from patient representatives about the disease burden they carry and the importance of involving patients’ insights in key strategic decisions from clinical development programs to the development of patient support programs. When engaging directly with patients, we follow strict engagement protocols and apply standardised remuneration principles. Patient safety is a top priority. We have strict drug safety and reporting processes in place, ensuring that patients using our products benefit safely from them. Scientific activities are performed in a patient-centric manner and according to internationally established standards. In its fourth year, the CSL Vifor Patient Academy continued to evolve in 2022. It includes: • 35 patient ambassadors who participated in numerous events and provided input into internal processes; • five global educational events that were organised throughout the past year with patient involvement focusing on nephrology, heart failure, rare disease and iron deficiency to raise awareness amongst employees; • two digital campaigns sponsored by CSL Vifor in 2022 for Rare Revolution Magazine to increase understanding of the burden of disease for IgAN and vasculitis; and • seven roundtables with heart failure patients working groups from across Europe organised by the Patient Academy. Under the umbrella of the Academy, a whitepaper entitled ‘Heart Failure, an inconvenient truth’ was published in September 2022 with the aim to advocate for a better quality of life in heart failure. This whitepaper is based on a pan-European survey among more than 600 heart failure patients and has been developed together with the following stakeholder groups: CSL Vifor, Pumping Marvellous (UK), AVEC (France), Herzschwäche Deutschland (Germany), and The Patients Voice (Netherlands) and Vintura (Netherlands). For this project, CSL Vifor was awarded SILVER by the Patient Partnership Index 2022. CSL Vifor’s commitment to patients through the Patient Academy
RkJQdWJsaXNoZXIy MjE2NDg3